The March 2026 quarter results underscore Apollo's ability to deliver consistent growth across its healthcare ecosystem, with net sales reaching an all-time high of ₹6,605.50 crores, up 1.98% sequentially and 18.12% year-on-year. Operating margins expanded to 15.31%, the highest in recent quarters, whilst the company maintained its leadership position in the hospital sector with a commanding presence across 16 cities.
Apollo's full-year FY26 performance has been equally impressive, with consolidated net profit for the nine months ending March 2026 reaching ₹1,942.10 crores, representing a 30.31% year-on-year increase. The company's ability to scale operations whilst improving profitability metrics reflects strong execution capabilities and favourable industry tailwinds in India's rapidly expanding healthcare sector.
Financial Performance: Margin Expansion Drives Profitability Surge
Apollo Hospitals' Q4 FY26 financial performance demonstrates remarkable operational leverage, with the company achieving its highest quarterly operating margin of 15.31%, up from 14.90% in Q3 FY26 and significantly ahead of the 13.76% recorded in Q4 FY25. This 155 basis point year-on-year margin expansion translated into operating profit (PBDIT excluding other income) of ₹1,011.00 crores, the highest quarterly figure on record.
| Metric (₹ Cr) | Mar'26 | Dec'25 | Sep'25 | Jun'25 | Mar'25 | QoQ Δ | YoY Δ |
|---|---|---|---|---|---|---|---|
| Net Sales | 6,605.50 | 6,477.40 | 6,303.50 | 5,842.10 | 5,592.20 | +1.98% | +18.12% |
| Operating Profit | 1,011.00 | 965.30 | 941.10 | 851.90 | 769.70 | +4.73% | +31.36% |
| Operating Margin % | 15.31% | 14.90% | 14.93% | 14.58% | 13.76% | +41 bps | +155 bps |
| Net Profit | 529.30 | 502.30 | 477.20 | 432.80 | 389.60 | +5.38% | +35.86% |
| PAT Margin % | 8.35% | 7.97% | 7.84% | 7.55% | 7.41% | +38 bps | +94 bps |
Revenue growth remained resilient across the quarter, with net sales advancing 1.98% sequentially despite typical seasonality patterns. The 18.12% year-on-year growth reflects Apollo's successful capacity expansion strategy and improved occupancy rates across its hospital network. Importantly, this top-line growth was accompanied by disciplined cost management, with employee costs as a percentage of sales declining to 11.69% from 12.96% in the year-ago quarter.
The company's profit before tax reached ₹721.50 crores in Q4 FY26, up 5.79% quarter-on-quarter and 39.97% year-on-year. The tax rate normalised to 23.59% from the elevated 29.24% in Q4 FY25, contributing to the strong net profit growth. Interest costs remained well-managed at ₹119.10 crores, representing just 1.80% of sales, whilst depreciation increased modestly to ₹224.40 crores, reflecting ongoing capital investments in healthcare infrastructure.
Operational Excellence: Capital Efficiency Reaches Multi-Year Highs
Apollo Hospitals' operational metrics paint a picture of a company firing on all cylinders. The half-yearly return on capital employed (ROCE) reached 17.41%, the highest level recorded in recent periods, whilst the latest annual ROCE stood at 17.91%—significantly ahead of the five-year average of 15.96%. This improvement in capital efficiency reflects both enhanced profitability and judicious capital allocation decisions.
The company's return on equity (ROE) has similarly strengthened, with the latest annual ROE at 18.39% compared to the five-year average of 14.68%. This 370 basis point improvement demonstrates Apollo's ability to generate superior returns for shareholders whilst maintaining a prudent balance sheet structure. The higher ROE indicates better capital efficiency and profitability, positioning Apollo favourably amongst healthcare peers.
✓ Key Operational Strengths
Capital Efficiency Leadership: Apollo's ROCE of 17.91% and ROE of 18.39% demonstrate exceptional management efficiency in deploying capital. The company's ability to generate ₹1.44 of sales for every rupee of capital employed (sales to capital employed ratio) reflects strong asset utilisation across its hospital network.
Debt Management: With a debt-to-EBITDA ratio of 2.40 times and net debt-to-equity of 0.53, Apollo maintains a moderate leverage profile that provides financial flexibility for growth investments whilst ensuring debt serviceability. The EBIT-to-interest coverage ratio of 4.43 times offers comfortable cushion for servicing obligations.
Apollo's balance sheet demonstrates prudent financial management, with shareholder funds growing to ₹8,212.30 crores in FY25 from ₹6,935.40 crores in FY24. Long-term debt increased to ₹4,417.00 crores from ₹2,235.60 crores, primarily to fund capacity expansion initiatives. Fixed assets expanded to ₹8,520.10 crores, reflecting significant capital investments in healthcare infrastructure, whilst current assets grew to ₹7,028.90 crores, providing adequate liquidity.
The company's cash flow generation remains robust, with operating cash flow of ₹2,136.00 crores in FY25, up from ₹1,920.00 crores in FY24. This strong operating cash generation funded capital expenditure of ₹3,380.00 crores, with the balance financed through debt. The closing cash position of ₹578.00 crores, combined with strong cash generation capabilities, provides Apollo with the financial resources to pursue growth opportunities.
Healthcare Sector Dynamics: Riding India's Wellness Wave
Apollo Hospitals operates in an exceptionally favourable industry environment, with India's healthcare sector experiencing structural growth driven by rising incomes, increasing health awareness, and expanding insurance penetration. The private hospital segment, in particular, is benefiting from capacity constraints in public healthcare infrastructure and growing preference for quality medical services amongst the middle class.
The company's diversified presence across hospitals, pharmacies, and primary care clinics positions it to capture multiple growth vectors within the healthcare ecosystem. Apollo's 16-city hospital network provides geographic diversification, whilst its focus on tertiary and quaternary care services commands premium pricing and drives superior margins compared to secondary care facilities.
Industry Context: Healthcare Demand Acceleration
India's healthcare expenditure is projected to grow at a compound annual growth rate exceeding 12% over the next five years, driven by demographic trends, lifestyle diseases, and medical tourism. Apollo's market leadership in the private hospital sector, combined with its integrated care delivery model, positions the company to outpace industry growth rates.
The post-pandemic environment has accelerated digital health adoption, with telemedicine and remote monitoring creating new revenue streams. Apollo's investments in digital health platforms and pharmacy networks provide additional growth levers beyond traditional hospital services.
Peer Comparison: Premium Valuation Reflects Quality Leadership
Apollo Hospitals commands a premium valuation relative to hospital sector peers, justified by its superior scale, operational efficiency, and consistent execution track record. With a market capitalisation of ₹1,19,423.94 crores, Apollo is the largest company in the hospital sector, significantly ahead of competitors in both size and profitability metrics.
| Company | P/E (TTM) | P/BV | ROE % | Debt/Equity | Div Yield % |
|---|---|---|---|---|---|
| Apollo Hospitals | 63.85 | 12.75 | 14.68 | 0.53 | 0.25 |
| Max Healthcare | 71.79 | 10.42 | 12.01 | 0.28 | 0.14 |
| Fortis Healthcare | 72.97 | 7.81 | 7.20 | 0.29 | 0.10 |
| Narayana Hrudayalaya | 46.97 | 9.58 | 24.25 | 0.13 | 0.24 |
| Aster DM Healthcare | 97.45 | 8.67 | 18.40 | 0.20 | 0.52 |
| Global Health | 58.10 | 8.98 | 15.69 | -0.07 | 0.04 |
Apollo's price-to-earnings ratio of 63.85 times trailing twelve-month earnings sits below the peer average of approximately 69 times, despite the company's superior scale and market position. However, the price-to-book value of 12.75 times represents a significant premium to the peer average of approximately 9.1 times, reflecting investor confidence in Apollo's asset quality and growth prospects.
The company's ROE of 14.68% trails some specialist peers like Narayana Hrudayalaya (24.25%) and Aster DM Healthcare (18.40%), but exceeds others including Max Healthcare (12.01%) and Fortis Healthcare (7.20%). Apollo's moderate debt-to-equity ratio of 0.53 provides balance sheet flexibility, whilst the dividend yield of 0.25% reflects a conservative payout policy favouring reinvestment for growth.
Valuation Analysis: Fair Value with Growth Optionality
At the current market price of ₹8,305.75, Apollo Hospitals trades at 63.85 times trailing earnings and 12.75 times book value, representing a fair valuation that incorporates the company's strong fundamentals and growth trajectory. The enterprise value-to-EBITDA multiple of 34.25 times and EV-to-EBIT of 45.33 times reflect investor willingness to pay a premium for quality healthcare assets with predictable cash flows.
The company's PEG ratio of 1.65 suggests the valuation is reasonable relative to earnings growth expectations, particularly considering Apollo's five-year EBIT growth rate of 39.35% and sales growth of 17.93%. The EV-to-sales ratio of 4.99 times and EV-to-capital employed of 8.67 times are elevated compared to broader market averages but justified by superior returns on capital and margin profile.
Apollo's valuation has transitioned to "Attractive" from "Fair" as of November 2025, reflecting improved operational performance and margin expansion. The stock trades approximately 0.96% below its 52-week high of ₹8,386.00, suggesting limited downside risk whilst maintaining upside potential as the company executes on its expansion strategy. The 24.34% premium to the 52-week low of ₹6,680.00 demonstrates strong investor support during market corrections.
Shareholding Pattern: Institutional Confidence Builds
Apollo Hospitals' shareholding structure reflects strong institutional confidence, with combined FII, mutual fund, and insurance holdings totalling 63.93% as of March 2026. Foreign institutional investors hold the largest stake at 42.62%, though this declined marginally by 0.92 percentage points quarter-on-quarter, potentially due to profit booking following the stock's strong performance.
| Category | Mar'26 | Dec'25 | Sep'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 28.02% | 28.02% | 28.02% | Stable |
| FII | 42.62% | 43.54% | 44.20% | -0.92% |
| Mutual Funds | 16.65% | 16.75% | 16.48% | -0.10% |
| Insurance | 4.66% | 3.64% | 3.46% | +1.02% |
| Other DII | 1.68% | 1.35% | 1.41% | +0.33% |
| Non-Institutional | 6.37% | 6.71% | 6.43% | -0.34% |
Promoter holding remained stable at 28.02% in Q4 FY26, following a 1.32 percentage point reduction in September 2025. The promoter group, led by PCR Investments Ltd (18.93%) and the Reddy family members, maintains strategic control whilst allowing substantial public float. Notably, promoter pledging stands at just 2.49%, indicating minimal financial stress.
Domestic institutional investors demonstrated increased conviction, with insurance companies raising their stake by 1.02 percentage points to 4.66% and other DIIs increasing holdings by 0.33 percentage points to 1.68%. Mutual fund holdings declined marginally by 0.10 percentage points to 16.65%, representing minor portfolio rebalancing rather than a loss of confidence. The presence of 359 mutual funds and 1,164 FIIs underscores broad-based institutional participation.
Stock Performance: Consistent Outperformance Across Timeframes
Apollo Hospitals has delivered exceptional returns across multiple time horizons, significantly outperforming the Sensex benchmark. The stock has generated positive alpha across all measured periods, demonstrating consistent value creation for shareholders. Over the past year, Apollo returned 18.84% compared to the Sensex's -7.99%, translating to alpha of 26.83 percentage points.
| Period | Apollo Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +2.34% | -0.43% | +2.77% |
| 1 Month | +7.25% | -5.29% | +12.54% |
| 3 Months | +9.13% | -9.34% | +18.47% |
| 6 Months | +12.35% | -11.92% | +24.27% |
| YTD | +17.94% | -11.90% | +29.84% |
| 1 Year | +18.84% | -7.99% | +26.83% |
| 3 Years | +86.99% | +21.62% | +65.37% |
| 5 Years | +155.79% | +48.55% | +107.24% |
The stock's technical positioning remains robust, with the current trend classified as "Bullish" since May 8, 2026. Apollo trades above all key moving averages—5-day (₹8,068.63), 20-day (₹7,885.88), 50-day (₹7,669.02), 100-day (₹7,463.46), and 200-day (₹7,511.89)—indicating strong momentum and broad-based buying support. The MACD indicator shows bullish signals on the weekly chart, whilst Bollinger Bands suggest continued upward momentum on both weekly and monthly timeframes.
Apollo's beta of 0.65 classifies it as a low-beta stock, indicating 35% lower volatility than the broader market. This defensive characteristic, combined with positive returns, places Apollo in the attractive "Low Risk High Return" quadrant. The risk-adjusted return of 0.97 over the past year, compared to the Sensex's -0.62, demonstrates superior risk-reward dynamics. Stock volatility of 19.42% remains manageable, particularly for a mid-cap healthcare name.
Notably, Apollo has underperformed the hospital sector by 2.94 percentage points over the past year, with the sector returning 21.78% compared to Apollo's 18.84%. This relative underperformance appears temporary, given Apollo's improving operational metrics and margin expansion trajectory. The stock's year-to-date return of 17.94% significantly outpaces the Sensex's -11.90%, highlighting Apollo's defensive growth characteristics during market volatility.
Investment Thesis: Quality Growth at Reasonable Valuation
Apollo Hospitals presents a compelling investment case built on four pillars: attractive valuation following recent corrections, good quality fundamentals, positive financial trends, and bullish technical indicators. The company's proprietary Mojo Score of 75/100 places it firmly in "BUY" territory, upgraded from "HOLD" on May 11, 2026, reflecting improving operational performance and market positioning.
The company's quality grade of "Good" reflects solid long-term financial performance, with five-year sales CAGR of 17.93% and EBIT growth of 39.35%. Apollo's ROCE of 16.84% demonstrates high management efficiency, whilst the debt-to-EBITDA ratio of 2.40 times indicates a healthy ability to service debt obligations. Institutional holdings of 65.61% underscore professional investor confidence in the company's prospects.
Key Strengths & Risk Factors
✅ KEY STRENGTHS
- Market Leadership: Largest private hospital chain with commanding presence across 16 cities and diversified service offerings
- Margin Expansion: Operating margins reached record 15.31% in Q4 FY26, up 155 bps YoY, demonstrating operational leverage
- Capital Efficiency: ROCE of 17.91% and ROE of 18.39% reflect superior returns on invested capital
- Consistent Growth: Five-year sales CAGR of 17.93% and EBIT growth of 39.35% demonstrate execution capabilities
- Strong Cash Generation: Operating cash flow of ₹2,136 crores in FY25 funds growth investments
- Institutional Confidence: 65.61% institutional holdings with broad-based participation from 1,164 FIIs and 359 mutual funds
- Technical Strength: Bullish trend with stock trading above all key moving averages
⚠️ KEY CONCERNS
- Premium Valuation: P/BV of 12.75x represents significant premium to peers, limiting margin of safety
- Leverage Increase: Long-term debt doubled to ₹4,417 crores in FY25 for expansion, increasing financial risk
- Sector Underperformance: Stock lagged hospital sector by 2.94% over past year despite strong fundamentals
- FII Selling: Foreign institutional ownership declined 0.92% in Q4 FY26, indicating some profit booking
- Regulatory Risks: Healthcare sector subject to pricing regulations and policy changes affecting profitability
- Capital Intensity: Hospital expansion requires significant capital expenditure, pressuring free cash flow
- Competition: Increasing competition from regional hospital chains and new entrants in key markets
Outlook: What to Watch in Coming Quarters
📈 POSITIVE CATALYSTS
- Capacity Ramp-Up: New hospital additions and bed capacity expansion driving occupancy improvements
- Margin Sustainability: Continued operating leverage as fixed costs spread over growing revenue base
- Digital Health: Telemedicine and digital platforms creating new revenue streams with minimal capital
- Medical Tourism: India's cost advantage attracting international patients post-pandemic
- Insurance Penetration: Rising health insurance adoption improving patient affordability and volumes
🚩 RED FLAGS
- Margin Pressure: Any reversal in operating margin expansion would disappoint elevated market expectations
- Debt Serviceability: Rising interest rates increasing cost of servicing ₹4,417 crore debt burden
- Occupancy Decline: Slower-than-expected ramp-up of new capacity affecting return on investments
- Regulatory Changes: Government price controls on medical procedures impacting revenue realisation
- Execution Delays: Postponement of planned capacity additions affecting growth trajectory
The Verdict: Attractive Entry Point for Quality Healthcare Play
Score: 75/100
For Fresh Investors: Apollo Hospitals offers an attractive entry point at current levels, combining market leadership, improving margins, and exposure to India's structural healthcare growth story. The recent upgrade to "BUY" from "HOLD" reflects improving fundamentals and reasonable valuation. Investors seeking long-term wealth creation in the healthcare sector should consider accumulating at current levels with a 12-18 month investment horizon.
For Existing Holders: Continue holding positions with confidence. The Q4 FY26 results validate the investment thesis, with record profitability and margin expansion demonstrating operational excellence. The company's ability to deliver consistent growth whilst improving capital efficiency justifies the premium valuation. Existing investors should maintain positions and consider adding on any near-term corrections below ₹8,000.
Fair Value Estimate: ₹8,800-9,200 (6-11% upside potential from current levels of ₹8,305.75)
Rationale: The BUY rating is supported by Apollo's market leadership position, record operating margins of 15.31%, improving ROCE of 17.91%, and strong institutional confidence reflected in 65.61% holdings. The company's five-year sales CAGR of 17.93% and EBIT growth of 39.35% demonstrate consistent execution capabilities. Whilst the P/BV of 12.75x represents a premium, it is justified by superior quality metrics and growth visibility. The bullish technical trend and positive financial momentum provide additional conviction for fresh accumulation.
Note- ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results, and all investments carry inherent risks including the potential loss of principal. The views expressed herein are based on information available as of the publication date and are subject to change without notice.
